Document is current
Any future updates will be listed below
-
Authors
Das, Rajdeep https://orcid.org/0000-0002-1041-4931
Sjöström, Martin https://orcid.org/0000-0002-2629-9966
Shrestha, Raunak
Yogodzinski, Christopher
Egusa, Emily A.
Chesner, Lisa N.
Chen, William S.
Chou, Jonathan https://orcid.org/0000-0003-1258-0391
Dang, Donna K.
Swinderman, Jason T.
Ge, Alex
Hua, Junjie T.
Kabir, Shaheen
Quigley, David A.
Small, Eric J. https://orcid.org/0000-0003-3191-6268
Ashworth, Alan
Feng, Felix Y. https://orcid.org/0000-0002-0963-7687
Gilbert, Luke A. https://orcid.org/0000-0001-5854-0825
- License Information
-
More Information
Article History
Received: 8 May 2020
Accepted: 15 July 2021
First Online: 29 July 2021
Competing interests
: F.Y.F. is a co-founder of PFS Genomics, serves on the Scientific Advisory Board of SerImmune, and has consulted for Astellas, Bayer, Blue Earth Diagnostics, Clovis, Genentech, Janssen, Myovant, Roivant, and Sanofi. A.A. is a co-founder of Tango Therapeutics, Azkarra Therapeutics, Ovibio Corporation; a consultant for SPARC, Bluestar, TopoRx, ProLynx, Earli, Cura; a member of the SAB of Genentech and GLAdiator; receives grant/research support from SPARC and AstraZeneca; A.A. also holds patents on the use of PARP inhibitors held jointly with AstraZeneca which he has benefitted financially (and may do so in the future) through the ICR Rewards to Inventors Scheme. L.A.G. has filed patents on CRISPR functional genomics and is a co-founder of Chroma Medicine. F.Y.F. and L.A.G. have filed a patent application related to targeting prostate cancer driver genes. The remaining authors declare no competing interests.
